bluebird bio Inc BLUE.OQ BLUE.O is expected to show a rise in quarterly revenue when it reports results on March 24 (estimated) for the period ending December 31 2024
The Somerville Massachusetts-based company is expected to report a 247.3% increase in revenue to $27.207 million from $7.83 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.The company's guidance on November 14 2024, for the period ended December 31, was for revenue of $25.000 million.
LSEG's mean analyst estimate for bluebird bio Inc is for a loss of $6.15 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for bluebird bio Inc is $8.00, above its last closing price of $3.96.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -6.65 | -7.29 | -6.20 | Beat | 14.9 |
Jun. 30 2024 | -9.96 | -8.33 | -8.40 | Missed | -0.8 |
Mar. 31 2024 | -8.83 | -8.81 | -7.20 | Beat | 18.3 |
Dec. 31 2023 | -13.01 | -13.24 | -15.60 | Missed | -17.8 |
Sep. 30 2023 | -13.45 | -13.50 | -13.20 | Beat | 2.2 |
Jun. 30 2023 | -14.37 | -14.31 | -13.40 | Beat | 6.4 |
Mar. 31 2023 | -5.37 | -7.40 | 4.20 | Beat | 156.8 |
Dec. 31 2022 | -7.41 | -8.72 | -16.20 | Missed | -85.8 |
This summary was machine generated March 21 at 13:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments